INTRODUCTION: The study aim is to investigate indications for breast magnetic resonance imaging (MRI) screening for high-risk women and to determine outcomes, correlation with routine imaging, and adherence to current guidelines for use. METHODS: We identified 200 patients undergoing 275 breast MRIs for high-risk surveillance from 2005 to 2008. Data collected included patient characteristics, need for additional imaging and/or biopsy, correlation with routine imaging, and outcomes. Gail scores were calculated for patients without hereditary breast cancer syndromes or previous chest radiation. Descriptive statistics were utilized for data summary. RESULTS: Two hundred patients underwent 275 breast MRIs for high-risk surveillance (mean age 45 years, range 18-76 years). Indications included BRCA mutation (n =21), history of chest radiation (n = 10), and perceived high risk (n =169). The mean Gail score for the latter group was 25% (range 10-46%); 32 (16%) patients had Gail score <20%. Of 275 MRIs, 49 (18%) required additional imaging and 21 (8%) prompted biopsy. Of 21 biopsies, 4 were malignant; 2 were also visible on routine imaging performed concurrently with breast MRI. The false-positive rate for breast MRI screening in our cohort of high-risk patients was 23%. CONCLUSION: The rate of cancer detection in high-risk patients undergoing breast MRI at our institution is similar to that of large, multicenter trials. Sixteen percent of patients undergoing breast MRI did not meet high-risk criteria. Because the need for additional imaging and biopsy remains high, further investigation is necessary to determine if this strategy is cost effective.
INTRODUCTION: The study aim is to investigate indications for breast magnetic resonance imaging (MRI) screening for high-risk women and to determine outcomes, correlation with routine imaging, and adherence to current guidelines for use. METHODS: We identified 200 patients undergoing 275 breast MRIs for high-risk surveillance from 2005 to 2008. Data collected included patient characteristics, need for additional imaging and/or biopsy, correlation with routine imaging, and outcomes. Gail scores were calculated for patients without hereditary breast cancer syndromes or previous chest radiation. Descriptive statistics were utilized for data summary. RESULTS: Two hundred patients underwent 275 breast MRIs for high-risk surveillance (mean age 45 years, range 18-76 years). Indications included BRCA mutation (n =21), history of chest radiation (n = 10), and perceived high risk (n =169). The mean Gail score for the latter group was 25% (range 10-46%); 32 (16%) patients had Gail score <20%. Of 275 MRIs, 49 (18%) required additional imaging and 21 (8%) prompted biopsy. Of 21 biopsies, 4 were malignant; 2 were also visible on routine imaging performed concurrently with breast MRI. The false-positive rate for breast MRI screening in our cohort of high-risk patients was 23%. CONCLUSION: The rate of cancer detection in high-risk patients undergoing breast MRI at our institution is similar to that of large, multicenter trials. Sixteen percent of patients undergoing breast MRI did not meet high-risk criteria. Because the need for additional imaging and biopsy remains high, further investigation is necessary to determine if this strategy is cost effective.
Authors: Sima Ehsani; Roberta M Strigel; Erica Pettke; Lee Wilke; Amye J Tevaarwerk; Wendy B DeMartini; Kari B Wisinski Journal: Breast J Date: 2015-03-17 Impact factor: 2.431
Authors: Courtney K Morrison; Leah C Henze Bancroft; Wendy B DeMartini; James H Holmes; Kang Wang; Ryan J Bosca; Frank R Korosec; Roberta M Strigel Journal: Invest Radiol Date: 2017-04 Impact factor: 6.016
Authors: Roberta M Strigel; Jennifer Rollenhagen; Elizabeth S Burnside; Mai Elezaby; Amy M Fowler; Frederick Kelcz; Lonie Salkowski; Wendy B DeMartini Journal: Acad Radiol Date: 2016-12-13 Impact factor: 3.173
Authors: Karen J Wernli; Wendy B DeMartini; Laura Ichikawa; Constance D Lehman; Tracy Onega; Karla Kerlikowske; Louise M Henderson; Berta M Geller; Mike Hofmann; Bonnie C Yankaskas Journal: JAMA Intern Med Date: 2014-01 Impact factor: 21.873
Authors: Roberta M Strigel; Erin Bravo; Amye J Tevaarwerk; Bethany M Anderson; Amy L Stella; Heather B Neuman Journal: Clin Breast Cancer Date: 2020-10-17 Impact factor: 3.225